GLEN ALLEN, Va., April 22, 2026

Adial Pharmaceuticals, Inc. announced the successful completion of demonstration batch production for its lead drug candidate AD04, marking a critical step toward initiating Phase 3 clinical development for the treatment of Alcohol Use Disorder (AUD). The company confirmed that the manufacturing process met all required regulatory specifications, including dissolution, blend uniformity, and content uniformity, enabling the transition to clinical and registration batch production.

Manufacturing Milestone Enables Late-Stage Development

The successful demonstration batch validates that the transferred manufacturing process is consistent, reproducible, and compliant with regulatory standards, a key requirement before advancing to Phase 3 trials. Notably, the batch achieved all prespecified quality attributes and matched the dissolution profile of the previous Phase 2 batch, confirming product consistency and formulation reliability.

This milestone also reflects a successful technology transfer to a new contract development and manufacturing organization (CDMO), improving efficiency, scalability, and readiness for commercial production. Such manufacturing validation is essential for ensuring quality assurance and regulatory compliance, particularly as the program progresses toward late-stage clinical evaluation and potential approval.

AD04 Targets Alcohol Use Disorder with Precision Approach

Advertisement

cGxPJobs Banner

AD04 is a genetically targeted serotonin-3 receptor antagonist designed to treat heavy drinking patients with Alcohol Use Disorder, addressing a significant unmet medical need. The therapy is being developed using a precision medicine approach, focusing on patients with specific genetic markers identified through proprietary diagnostic testing.

Prior clinical data, including results from the ONWARD study, demonstrated promising reductions in alcohol consumption without major safety or tolerability concerns, supporting continued advancement. AUD remains a serious global health issue, with limited effective therapies and high relapse rates, making the development of targeted treatments like AD04 particularly important.

Regulatory Readiness and Commercial Outlook

With the completion of the demonstration batch, Adial is now positioned to manufacture clinical and registration batches required for its planned Phase 3 trial, as well as generate data necessary for updates to its Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

This achievement strengthens the company’s ability to progress regulatory interactions and accelerate development timelines, bringing AD04 closer to potential commercialization. In addition to AUD, AD04 may have applications in other addiction-related disorders, including opioid use disorder, gambling addiction, and obesity, expanding its potential impact.

The milestone highlights the critical role of pharmaceutical manufacturing excellence in drug development, where process validation, consistency, and regulatory compliance are essential for success. By achieving this key step, Adial Pharmaceuticals demonstrates strong progress in advancing AD04 toward late-stage clinical trials and potential market entry, offering hope for more effective and personalized treatments for addiction disorders.

Source: Adial Pharmaceuticals press release